BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

...Histogen to trade on NASDAQ following reverse-merger with Conatus Histogen Inc. proposed to merge with Conatus Pharmaceuticals Inc....
...traded company that would advance Histogen’s pipeline of regenerative medicines for aesthetic and orthopedic indications. Conatus...
...Staff Writer Biohaven Pharmaceutical Holding Co. Ltd. Denali Therapeutics Inc. Concert Pharmaceuticals Inc. Annovis Bio Inc. Histogen Inc. CellFE Inc. Lyra Therapeutics Inc. Conatus Pharmaceuticals Inc....
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...Conatus cuts headcount by 40% to extend runway Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40%...
...emricasan, failed in a Phase IIb trial. Conatus lost $0.63 (69%) to $0.29 Tuesday (see “Conatus...
...tnx-650, anti-IL13) Ryaltris, mometasone/olopatadine (gsp 301) Seven-day contraceptive patch, Twirla (AG200-15, ag-200-15, Agile Patch, estradiol/levonorgestrel) Agile Therapeutics Inc. Almirall S.A. Conatus Pharmaceuticals Inc. Edding...
BioCentury | Mar 21, 2019
Clinical News

Conatus sinks after NASH therapy misses fibrosis endpoint

...a 1-stage improvement in fibrosis with no worsening of steatohepatitis at week 72 vs. placebo. Conatus Pharmaceuticals Inc....
...NASH cirrhosis and severe portal hypertension. That endpoint measured mean hepatic venous pressure gradient (see "Conatus...
...a path forward. Novartis has exclusive, worldwide rights to the pan-caspase protease inhibitor from Conatus. Conatus...
BioCentury | Dec 6, 2018
Clinical News

Conatus' emricasan misses in Phase IIb for NASH cirrhosis

...Novartis AG (SIX:NOVN; NYSE:NVS) has exclusive, worldwide rights to the pan-caspase protease inhibitor from Conatus. Conatus Pharmaceuticals Inc....
...24 Status: Phase IIb data Milestone: Extension study data (mid-2019) Chris Lieu emricasan (IDN-6556, PF-03491390, PF-3491390, VAY785) Novartis AG Conatus Pharmaceuticals Inc. Caspases Non-alcoholic...
BioCentury | Dec 6, 2018
Clinical News

Conatus down on Phase IIb NASH miss

...Novartis AG (SIX:NOVN; NYSE:NVS) has exclusive, worldwide rights to the pan-caspase protease inhibitor from Conatus. Conatus...
...announced the news on Wednesday when U.S. markets were closed. Chris Lieu emricasan (IDN-6556, PF-03491390, PF-3491390, VAY785) Novartis AG Conatus Pharmaceuticals Inc. Caspases Non-alcoholic...
BioCentury | Nov 2, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

...II compound emricasan, a pan-caspase protease inhibitor. Novartis has exclusive, worldwide rights to emricasan from Conatus Pharmaceuticals Inc....
BioCentury | Oct 29, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

...II compound emricasan, a pan-caspase protease inhibitor. Novartis has exclusive, worldwide rights to emricasan from Conatus Pharmaceuticals Inc....
BioCentury | Apr 6, 2018
Clinical News

Conatus' emricasan misses in Phase IIb in liver transplant patients

...Fibrosis Score of F3-F5), emricasan significantly improved response rate vs. placebo (95% vs. 58.3%, p=0.019). Conatus...
...SIX:NOVN) has exclusive, worldwide rights to emricasan from Conatus (see BioCentury, May 4, 2017) . Conatus Pharmaceuticals Inc....
...modified Histological Activity Index Status: Phase IIb data Milestone: NA Allison Johnson emricasan (IDN-6556, PF-03491390, PF-3491390, VAY785) Novartis AG Conatus Pharmaceuticals Inc. Caspases...
BioCentury | Apr 5, 2018
Clinical News

Conatus falls as emricasan misses in liver transplant patients

...Fibrosis Score of F3-F5), emricasan significantly improved response rate vs. placebo (95% vs. 58.3%, p=0.019). Conatus...
...are expected next half. Novartis AG (NYSE:NVS; SIX:NOVN) has exclusive, worldwide rights to emricasan from Conatus...
...The company announced the news after market hours on Wednesday. Allison Johnson emricasan (IDN-6556, PF-03491390, PF-3491390, VAY785) Novartis AG Conatus Pharmaceuticals Inc. Caspases...
BioCentury | Sep 16, 2017
Strategy

Passing the baton

...study is expected to start this year. Novartis gained exclusive, worldwide rights to emricasan from Conatus Pharmaceuticals Inc....
...Thousand Oaks, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Conatus Pharmaceuticals Inc....
Items per page:
1 - 10 of 92
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

...Histogen to trade on NASDAQ following reverse-merger with Conatus Histogen Inc. proposed to merge with Conatus Pharmaceuticals Inc....
...traded company that would advance Histogen’s pipeline of regenerative medicines for aesthetic and orthopedic indications. Conatus...
...Staff Writer Biohaven Pharmaceutical Holding Co. Ltd. Denali Therapeutics Inc. Concert Pharmaceuticals Inc. Annovis Bio Inc. Histogen Inc. CellFE Inc. Lyra Therapeutics Inc. Conatus Pharmaceuticals Inc....
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...Conatus cuts headcount by 40% to extend runway Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40%...
...emricasan, failed in a Phase IIb trial. Conatus lost $0.63 (69%) to $0.29 Tuesday (see “Conatus...
...tnx-650, anti-IL13) Ryaltris, mometasone/olopatadine (gsp 301) Seven-day contraceptive patch, Twirla (AG200-15, ag-200-15, Agile Patch, estradiol/levonorgestrel) Agile Therapeutics Inc. Almirall S.A. Conatus Pharmaceuticals Inc. Edding...
BioCentury | Mar 21, 2019
Clinical News

Conatus sinks after NASH therapy misses fibrosis endpoint

...a 1-stage improvement in fibrosis with no worsening of steatohepatitis at week 72 vs. placebo. Conatus Pharmaceuticals Inc....
...NASH cirrhosis and severe portal hypertension. That endpoint measured mean hepatic venous pressure gradient (see "Conatus...
...a path forward. Novartis has exclusive, worldwide rights to the pan-caspase protease inhibitor from Conatus. Conatus...
BioCentury | Dec 6, 2018
Clinical News

Conatus' emricasan misses in Phase IIb for NASH cirrhosis

...Novartis AG (SIX:NOVN; NYSE:NVS) has exclusive, worldwide rights to the pan-caspase protease inhibitor from Conatus. Conatus Pharmaceuticals Inc....
...24 Status: Phase IIb data Milestone: Extension study data (mid-2019) Chris Lieu emricasan (IDN-6556, PF-03491390, PF-3491390, VAY785) Novartis AG Conatus Pharmaceuticals Inc. Caspases Non-alcoholic...
BioCentury | Dec 6, 2018
Clinical News

Conatus down on Phase IIb NASH miss

...Novartis AG (SIX:NOVN; NYSE:NVS) has exclusive, worldwide rights to the pan-caspase protease inhibitor from Conatus. Conatus...
...announced the news on Wednesday when U.S. markets were closed. Chris Lieu emricasan (IDN-6556, PF-03491390, PF-3491390, VAY785) Novartis AG Conatus Pharmaceuticals Inc. Caspases Non-alcoholic...
BioCentury | Nov 2, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

...II compound emricasan, a pan-caspase protease inhibitor. Novartis has exclusive, worldwide rights to emricasan from Conatus Pharmaceuticals Inc....
BioCentury | Oct 29, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

...II compound emricasan, a pan-caspase protease inhibitor. Novartis has exclusive, worldwide rights to emricasan from Conatus Pharmaceuticals Inc....
BioCentury | Apr 6, 2018
Clinical News

Conatus' emricasan misses in Phase IIb in liver transplant patients

...Fibrosis Score of F3-F5), emricasan significantly improved response rate vs. placebo (95% vs. 58.3%, p=0.019). Conatus...
...SIX:NOVN) has exclusive, worldwide rights to emricasan from Conatus (see BioCentury, May 4, 2017) . Conatus Pharmaceuticals Inc....
...modified Histological Activity Index Status: Phase IIb data Milestone: NA Allison Johnson emricasan (IDN-6556, PF-03491390, PF-3491390, VAY785) Novartis AG Conatus Pharmaceuticals Inc. Caspases...
BioCentury | Apr 5, 2018
Clinical News

Conatus falls as emricasan misses in liver transplant patients

...Fibrosis Score of F3-F5), emricasan significantly improved response rate vs. placebo (95% vs. 58.3%, p=0.019). Conatus...
...are expected next half. Novartis AG (NYSE:NVS; SIX:NOVN) has exclusive, worldwide rights to emricasan from Conatus...
...The company announced the news after market hours on Wednesday. Allison Johnson emricasan (IDN-6556, PF-03491390, PF-3491390, VAY785) Novartis AG Conatus Pharmaceuticals Inc. Caspases...
BioCentury | Sep 16, 2017
Strategy

Passing the baton

...study is expected to start this year. Novartis gained exclusive, worldwide rights to emricasan from Conatus Pharmaceuticals Inc....
...Thousand Oaks, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Conatus Pharmaceuticals Inc....
Items per page:
1 - 10 of 92